SG11201807134RA - Transposon system and methods of use - Google Patents
Transposon system and methods of useInfo
- Publication number
- SG11201807134RA SG11201807134RA SG11201807134RA SG11201807134RA SG11201807134RA SG 11201807134R A SG11201807134R A SG 11201807134RA SG 11201807134R A SG11201807134R A SG 11201807134RA SG 11201807134R A SG11201807134R A SG 11201807134RA SG 11201807134R A SG11201807134R A SG 11201807134RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- san diego
- california
- pct
- rule
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 102000008579 Transposases Human genes 0.000 abstract 1
- 108010020764 Transposases Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004520 electroporation Methods 0.000 abstract 1
- 238000012239 gene modification Methods 0.000 abstract 1
- 230000005017 genetic modification Effects 0.000 abstract 1
- 235000013617 genetically modified food Nutrition 0.000 abstract 1
- 229910052754 neon Inorganic materials 0.000 abstract 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 210000002262 tip cell Anatomy 0.000 abstract 1
- 230000035899 viability Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
GFPr% EZI Viability (AAD-ve) FIGURE 1 100 Et 60 u_ 40- P' 4D nucleofector tip) P3 kit Seven, ands Polymer electrodes 4ES 100u1 Saitition T 2400Vi2Omel pulse 5 141 Gold-plated tip Cell nu , Tter Transfe004 . me T VE311 cot Electroporation technology Neon W O 20 17 / 147538 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/147538 Al 31 August 2017 (31.08.2017) WIPO I PCT (51) International Patent Classification: C12N 15/85 (2006.01) C12N 15/90 (2006.01) (21) International Application Number: PCT/US2017/019531 (22) International Filing Date: 24 February 2017 (24.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/300,387 26 February 2016 (26.02.2016) US (71) Applicant: POSEIDA THERAPEUTICS, INC. [US/US]; 4242 Campus Point Ct #700, San Diego, Califor- nia 92121 (US). (72) Inventors; and (71) Applicants : SHEDLOCK, Devon [US/US]; 4242 Cam- pus Point Ct #700, San Diego, California 92121 (US). HERMANSON, David [US/US]; 4242 Campus Point Ct #700, San Diego, California 92121 (US). (72) Inventor: OSTERTAG, Eric; 4242 Campus Point Ct #700, San Diego, California 92121 (US). (74) Agents: ELRIFI, Ivor R. et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, Dis-Published: trict of Columbia 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: TRANSPOSON SYSTEM AND METHODS OF USE Day 1 post EP (57) : Disclosed are methods for the ex-vivo genetic modification of an immune cell comprising delivering to the immune cell, (a) a nucleic acid or amino acid sequence comprising a sequence encoding a transposase enzyme and (b) a recombinant and non-naturally occurring DNA sequence comprising a DNA sequence encoding a transposon. 111111111111110111011111111111010111110111010111111111110110111110111111111110111111
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662300387P | 2016-02-26 | 2016-02-26 | |
| PCT/US2017/019531 WO2017147538A1 (en) | 2016-02-26 | 2017-02-24 | Transposon system and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807134RA true SG11201807134RA (en) | 2018-09-27 |
Family
ID=58314517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807134RA SG11201807134RA (en) | 2016-02-26 | 2017-02-24 | Transposon system and methods of use |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3420090A1 (en) |
| JP (1) | JP2019506177A (en) |
| KR (1) | KR20180131545A (en) |
| CN (1) | CN109312361A (en) |
| AU (1) | AU2017224111A1 (en) |
| BR (1) | BR112018067536A2 (en) |
| CA (1) | CA3015642A1 (en) |
| IL (1) | IL261343A (en) |
| MX (1) | MX2018010288A (en) |
| RU (1) | RU2018133691A (en) |
| SG (1) | SG11201807134RA (en) |
| WO (1) | WO2017147538A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190119636A1 (en) * | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| CA3047313A1 (en) | 2016-12-16 | 2018-06-21 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| CN108728477B (en) * | 2017-04-24 | 2022-02-22 | 华东理工大学 | Efficient transposition mutation system and construction method |
| WO2019046815A1 (en) * | 2017-08-31 | 2019-03-07 | Poseida Therapeutics, Inc. | Transposon system and methods of use |
| AU2018329741A1 (en) * | 2017-09-08 | 2020-03-19 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression |
| US10329543B2 (en) | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
| WO2019246486A2 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
| CN111926041B (en) * | 2020-10-16 | 2020-12-25 | 广州吉妮欧生物科技有限公司 | SARS-CoV-2 pseudovirus mouse internal packaging system and its preparation method |
| CN114246986B (en) * | 2021-12-29 | 2022-08-23 | 中国人民解放军陆军军医大学 | Cardiovascular implant based on in-situ immune response regulation and control and preparation method thereof |
| CN116590341A (en) * | 2023-07-13 | 2023-08-15 | 山东维真生物科技有限公司 | adenovirus-PiggyBac system and preparation method and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US9228180B2 (en) | 2007-07-04 | 2016-01-05 | Max-Delbruck-Centrum Fur Molekulare Medizin | Polypeptide variants of sleeping beauty transposase |
| WO2010099301A2 (en) * | 2009-02-25 | 2010-09-02 | The Johns Hopkins University | Piggybac transposon variants and methods of use |
| EP2401367B1 (en) * | 2009-02-26 | 2016-11-30 | Transposagen Biopharmaceuticals, Inc. | Hyperactive piggybac transposases |
| US20130045491A1 (en) * | 2011-07-19 | 2013-02-21 | Derya Unutmaz | Methods for activating t cells |
| WO2014077863A1 (en) * | 2012-11-19 | 2014-05-22 | Nature Technology Corporation | Replicative minicircle vectors with improved expression |
-
2017
- 2017-02-24 WO PCT/US2017/019531 patent/WO2017147538A1/en active Application Filing
- 2017-02-24 RU RU2018133691A patent/RU2018133691A/en not_active Application Discontinuation
- 2017-02-24 BR BR112018067536A patent/BR112018067536A2/en not_active IP Right Cessation
- 2017-02-24 EP EP17711046.7A patent/EP3420090A1/en not_active Withdrawn
- 2017-02-24 CA CA3015642A patent/CA3015642A1/en not_active Abandoned
- 2017-02-24 CN CN201780025816.1A patent/CN109312361A/en active Pending
- 2017-02-24 MX MX2018010288A patent/MX2018010288A/en unknown
- 2017-02-24 AU AU2017224111A patent/AU2017224111A1/en not_active Abandoned
- 2017-02-24 JP JP2018544891A patent/JP2019506177A/en active Pending
- 2017-02-24 KR KR1020187027345A patent/KR20180131545A/en unknown
- 2017-02-24 SG SG11201807134RA patent/SG11201807134RA/en unknown
-
2018
- 2018-08-23 IL IL261343A patent/IL261343A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3420090A1 (en) | 2019-01-02 |
| AU2017224111A1 (en) | 2018-09-13 |
| CA3015642A1 (en) | 2017-08-31 |
| CN109312361A (en) | 2019-02-05 |
| BR112018067536A2 (en) | 2019-02-05 |
| MX2018010288A (en) | 2019-06-06 |
| WO2017147538A1 (en) | 2017-08-31 |
| KR20180131545A (en) | 2018-12-10 |
| RU2018133691A3 (en) | 2020-07-29 |
| RU2018133691A (en) | 2020-03-26 |
| JP2019506177A (en) | 2019-03-07 |
| IL261343A (en) | 2018-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807134RA (en) | Transposon system and methods of use | |
| SG11201909203WA (en) | Tissue selective transgene expression | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201908658TA (en) | Nucleobase editors comprising nucleic acid programmable dna binding proteins | |
| SG11201901364VA (en) | Engineered target specific nucleases | |
| SG11201908489XA (en) | De novo synthesized combinatorial nucleic acid libraries | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
| SG11201901531TA (en) | Regulation of gene expression using engineered nucleases | |
| SG11201909432SA (en) | Compounds for increasing genome editing efficiency | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201907056XA (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| SG11201903674YA (en) | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201808552XA (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| SG11201803593QA (en) | Engineered nucleic-acid targeting nucleic acids | |
| SG11202000145XA (en) | Methods and systems for conditionally regulating gene expression | |
| SG11201803169WA (en) | Cellulase variants and polynucleotides encoding same | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201906301UA (en) | Methods of manufacture of nut flours and formulations for oral immunotherapy | |
| SG11201407343XA (en) | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof | |
| SG11201909864TA (en) | Tcr and peptides |